Opendoor Technologies Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Opendoor Technologies Inc trades at $2.31 (market cap $2.20B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Opendoor Technologies Inc and SELLAS Life Sciences Group Inc. Common Stock are close in size by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.
| OPEN | SLS | |
|---|---|---|
Market Cap | $2.20B | $2.28B |
Volume | 35,582,488 | 3,128,960 |
Sector | Real Estate | Health |
52-Week High | $9.37 | $15.46 |
52-Week Low | $2.27 | $1.39 |
Typical Hold Time | 33 Days | — |
Enterprise Value | $3.27B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
Opendoor Technologies trades at $2.29, up 0.88% with a bearish technical outlook. The company shows concerning fundamentals with a -46.74% net income margin and -$1.3B net loss despite $4.37B revenue. Recent earnings misses and negative cash flow trends highlight operational challenges, though mortgage expansion to 35-40 states by end-2026 offers potential growth. Analyst consensus is mixed with 26.9% buy ratings but a $4.92 price target suggesting 115% upside from current levels.
The stock presents high-risk speculative potential with significant operational turnaround required. While valuation appears attractive at 0.62 P/S ratio, persistent losses and housing market sensitivity create substantial downside risk. The mortgage expansion initiative could drive recovery if execution improves, but investors face volatility from rate sensitivity and competitive pressures in the iBuyer space.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →